Kymera Therapeutics (KYMR) Receivables - Net (2020 - 2025)

Kymera Therapeutics (KYMR) has 6 years of Receivables - Net data on file, last reported at $40.0 million in Q2 2025.

• On a quarterly basis, Receivables - Net rose 2247.42% year-over-year to $40.0 million in Q2 2025; TTM through Jun 2025 was $40.0 million, a 2247.42% increase from a year earlier, with the FY2024 full-year figure at $947000.0, down 94.95% from the prior year.
• Receivables - Net for Q2 2025 stood at $40.0 million, up from $20.0 million in the prior quarter.
• Over the last five years, Receivables - Net for KYMR reached as high as $40.0 million in Q2 2025 and fell as low as $135000.0 in Q4 2021.
• Historically, Receivables - Net has averaged $6.3 million across 5 years, with a median of $2.0 million in 2024.
• Across the five-year window, Receivables - Net tumbled 94.95% in 2024 and surged 2247.42% in 2025, its largest moves.
• Year by year, Receivables - Net stood at $135000.0 in 2021, then soared by 2034.81% to $2.9 million in 2022, then soared by 551.01% to $18.8 million in 2023, then tumbled by 94.95% to $947000.0 in 2024, then surged by 4123.86% to $40.0 million in 2025.
• Per Business Quant data, the three most recent Receivables - Net figures were $40.0 million in Q2 2025, $20.0 million in Q1 2025, and $947000.0 in Q4 2024.